Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC. (NCT06327178) | Nanfang Hospital, Southern Medical University | 2023-10-01 |
Track Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC automatically
Every clearance here is in the API, with alerts when new ones post.